API Micronization: Jet Milling and Particle Engineering
A batch of drug substance can pass assay and still fail where it matters. The dissolution result drifts or an inhaler delivers less fine particle dose, and the cause is particle size rather than chemistry. API micronization is the usual remedy, but the mill that fixes the size can also change the surface of the crystal. This guide explains the jet milling route, from mill mechanics and particle size targets to solid-state side effects, ICH controls and alternatives. It draws on peer-reviewed reviews and the ICH Q6A and Q7 guidelines, plus the formulation support Global Formulation gives pharmaceutical developers.
API Micronization: Why Particle Size Drives Performance
Particle size sets the surface area that a drug offers to fluid, and it sets how a powder behaves in air. A review of solubility enhancement techniques notes that as a particle becomes smaller, its surface area to volume ratio increases and gives greater interaction with the solvent. ICH Q6A makes the regulatory point: for some drug substances in solid or suspension products, particle size can have a significant effect on dissolution rates, bioavailability and stability. In those cases the guideline expects a particle size distribution test with acceptance criteria.
| Product or Route | Why Particle Size Matters | Source |
|---|---|---|
| Oral solid with dissolution-limited absorption | Micronization raises the dissolution rate through surface area but does not raise equilibrium solubility | Solubility review (PMC3399483) |
| Dry powder inhaler or inhaled aerosol | Aerodynamic diameters of about 1 to 5 µm suit aerosol generation; cohesiveness rises below 1 µm and falls above 5 µm | Inhalable particle review (PMC10748168) |
| Oral suspension | A particle size distribution test and criteria can be appropriate, performed at release | ICH Q6A |
| Injectable suspension | A particle size distribution test is considered alongside dissolution, with redispersibility also assessed | ICH Q6A |
Our guide to solubility enhancement techniques for poorly soluble drugs places micronization among the other options. Our guide to nasal and pulmonary drug delivery explains the inhaler side of the same size window.
Once size is the goal, the mill is the tool, and in practice that usually means a jet mill.
Jet Milling Pharmaceutical Powders: Mechanics and Process Variables
A jet mill breaks particles with gas, not with grinding media. High-velocity jets of air or nitrogen accelerate the powder so that particles collide with each other and with the chamber walls. A review of dry powder inhaler stability describes these repeated impacts as fracturing the particles, and it lists fluid impact, opposed jet, spiral, oval chamber and fluidised-bed opposed jet designs. Because a classifier lets only small enough particles leave, the product distribution is narrower than a simple grinder gives.
The Wikipedia article on jet mills explains the spiral design. Feed enters through a venturi, tangential gas jets create a vortex, and the gas leaves through a central outlet. Centrifugal force pushes large particles towards the wall, where they keep being milled. Small particles stay near the centre and leave with the gas.
| Variable | Effect on the Product | Source |
|---|---|---|
| Grinding gas pressure | Higher pressure generally shifts the size distribution finer | Micronization summary |
| Feed rate | Lower feed rate generally shifts the distribution finer; the ratio of pressure to feed rate is the key pairing | Micronization summary |
| Specific energy | Energy input per unit mass is described as the principal factor governing size and the basis for scaling from laboratory to commercial | Micronization summary |
| Classifier | Sets the cut-off for particles that leave; the inhalable-particle review notes that reaching finer sizes takes longer | PMC10748168 |
| Material properties | Elasticity, fracture behaviour, crystallinity and feed characteristics influence the result | Jet mill article |
| Gas expansion | Cooling as the gas expands suits heat-sensitive and meltable materials | PMC10748168 |
Size is only half of the result, because the same energy that fractures a crystal also changes its surface.
Amorphous Content, Cohesion and Post-Milling Conditioning
Fracturing a crystal does more than make it smaller. The dry powder inhaler stability review states that excess milling energy can cause mechanical activation and local amorphous sites at the particle surface. Jet-milled powder is also often extremely cohesive and prone to strong agglomeration, because surface energy and electrostatic charge rise. Together these effects mean the powder measured on the day of milling can differ from the powder used later.
| Effect | What Happens | Control |
|---|---|---|
| Surface amorphous sites | Mechanical activation creates disordered regions that can recrystallise during storage at high humidity | Detect with isothermal microcalorimetry or dynamic vapour sorption; condition the powder |
| Agglomeration | Raised surface energy and charge, and recrystallisation, can form strong agglomerates; milling intensity changes the amount of amorphous content | Conditioning, particle coating or co-milling with additives |
| Electrostatic charge | In a mannitol study, net charge increased as particle size decreased, which strengthened cohesion and lowered the fine particle fraction | Characterise charge and cohesion on the milled powder |
| Solid-state form | ICH Q6A says polymorphic forms, including amorphous forms, can affect performance, and the appropriate solid state should then be specified | X-ray powder diffraction, thermal analysis, Raman or solid-state NMR |
Conditioning is the standard answer. The review describes holding milled powder at controlled humidity and at a temperature above its glass transition temperature. Absorbed water lowers the glass transition temperature and raises molecular mobility, so the amorphous content recrystallises in a controlled way. It reports that accelerated temperature and humidity exposure improves post-micronization stability by relaxing the structure and reducing amorphous content and aggregation.
Other remedies are described too. The review reports dry coating of jet-milled particles with a force control agent such as magnesium stearate. Mechanofusion applied the coating and improved flowability and aerosol performance, with little or no loss of size. It also describes co-milling with additives, and notes that wet milling lets amorphous regions crystallise immediately in aqueous media.
Controls on size and solid state belong in the specification, which is where the guidelines come in.
Particle Size Controls: ICH Q6A, ICH Q7 and Measurement
A micronized API needs a specification, a method and a GMP system around the mill. ICH Q6A says particle size distribution testing should be carried out where size affects dissolution rate, bioavailability or stability, and acceptance criteria should be provided. ICH Q7 states that physical manipulation of particle size, such as milling and micronizing, should be conducted at least to the standards of that guide. Laser diffraction is the usual way to report the result as D10, D50 and D90.
| Control | What the Guideline or Source Says | Source |
|---|---|---|
| Particle size specification | Test the distribution with an appropriate procedure and give acceptance criteria; the test can be in-process or at release depending on its relevance to performance | ICH Q6A |
| Solid-state specification | Where forms differ in performance, specify the appropriate solid state and monitor it with suitable techniques | ICH Q6A |
| GMP scope | Milling and micronizing of an API are physical processing steps expected to meet ICH Q7 | ICH Q7 |
| Carry-over control | Residue adhering to the wall of a micronizer is the guide's own example of carry-over between batches | ICH Q7 |
| Cleaning validation | Swab sampling can be impractical on small intricate equipment such as micronizers, so rinsing or direct extraction methods are chosen as appropriate | ICH Q7 |
| Reprocessing | Repeating a milling step that is part of the established process is generally acceptable; if used for a majority of batches it should become part of the standard process | ICH Q7 |
| Measurement | Laser diffraction under USP chapter 429 and ISO 13320, reported as D10, D50 and D90 | Micronization summary |
Pairing the size result with a solid-state result is good practice, because the milling that sets size can change the surface. Our guides to quality by design in formulation development and the FDA, ICH and USP regulatory pathway show how these controls fit a filing. Our guide to drug-excipient compatibility studies covers the preformulation work that precedes milling decisions.
Micronization is one route among several, and the better choice depends on the attribute that has to change.
Particle Engineering Drug Substance: Top-Down and Bottom-Up Options
Particle engineering splits into top-down and bottom-up families. Top-down methods such as milling and micronization are cost-effective and suit compounds with known properties, according to the review of inhalable particles. Their main challenges are agglomeration and altered compound characteristics. Bottom-up methods build particles from molecules and give precise control over size, shape and distribution, but they are often more complex and expensive.
| Route | Principle | Strength | Limitation |
|---|---|---|---|
| Jet milling | Gas-driven particle impacts with classification | Convenient, low cost, continuous and suited to heat-sensitive materials | Cohesive powder, surface amorphous sites and longer time to reach finer sizes |
| Wet media milling and high-pressure homogenisation | Size reduction in a liquid medium | Amorphous regions crystallise immediately in aqueous media; fluid energy milling can pre-micronize feed for homogenisation | Needs a liquid medium and often a prior size reduction step |
| Spray drying | Droplets dried in a hot gas stream | Tunes size, density, morphology and surface composition in one continuous step | Amorphous product risk; see our spray drying guide |
| Crystallisation and other bottom-up methods | Particles built from solution | Precise control over size, shape and distribution | Often more complex and expensive |
| Dry coating and co-milling | Force control agent applied by mechanofusion, or additives milled with the API | Reduces interparticle forces and improves flowability and aerosol performance | Adds an excipient to the particle surface |
The review notes that the choice depends on the compound and the therapeutic goal, and that a combination of both approaches can be used. A flow-limited powder can call for a bottom-up particle or a dry coating rather than a finer mill setting. Our guide to pharmaceutical granulation technology covers the flow side of that decision.
Choosing and transferring a route is easier with a partner who has run more than one.
Working With a Pharmaceutical Formulation Consultant and CDMO
API micronization sits between solid-state chemistry, powder engineering and GMP, so a decision in one area affects the others. A pharmaceutical formulation consultant defines the target attribute, screens mills and parameters, and characterises the milled powder. Pharmaceutical product development services extend that work to stability design, specifications and regulatory documentation. Contract formulation CDMO support then carries the validated process into a facility that runs it under the right GMP standard.
- Define the target attribute — dissolution rate, aerodynamic performance or suspension behaviour.
- Characterise the API — thermal behaviour, breakage behaviour and starting particle size.
- Screen the mill and parameters — gas pressure, feed rate and classifier setting.
- Characterise the milled powder — size distribution, solid state, moisture sorption and cohesion.
- Condition and test stability — include humidity exposure on milled material.
- Set the specification — particle size and solid-state criteria in line with ICH Q6A.
- Transfer under GMP — define cleaning, carry-over and reprocessing rules in line with ICH Q7.
Our pharmaceutical and healthcare range shows where drug substance engineering sits among the dosage forms. Our guide to choosing a pharmaceutical formulation consultant explains how to select a partner. Global Formulation provides mill and parameter screening, solid-state characterisation, conditioning studies, specification support and transfer to a CDMO. Drug-specific particle size targets, API loadings and release data stay outside this guide by design.
Frequently Asked Questions
What is API micronization?
API micronization is the reduction of drug substance particle size to the micrometre range by fracturing particles with mechanical energy or shear. Jet milling is a common practice for doing this in the pharmaceutical industry.
The aim is to raise surface area for dissolution or to bring particles into the aerodynamic range that suits inhalation.
Because the process changes the particle surface as well as its size, the milled powder needs its own characterisation and stability data.
How does a jet mill micronize a drug substance?
A jet mill uses high-velocity jets of air or nitrogen to accelerate powder so that particles collide with each other and with the chamber walls. The repeated impacts fracture the particles.
A classifier then controls which particles leave. Coarse particles stay in the chamber for further milling, and particles that reach the target size exit with the gas.
No grinding media are involved, and the cooling from gas expansion suits heat-sensitive materials.
Does micronization improve the solubility of a drug?
No. A published review states that micronization increases the dissolution rate through increased surface area but does not increase equilibrium solubility.
That is why it suits drugs whose absorption is limited by dissolution rate. The review notes that micronization is not suitable for drugs with a high dose number, because the saturation solubility is unchanged.
Where the crystalline solubility itself is the limit, formulators look to other routes such as amorphous solid dispersions.
What particle size is needed for inhaled drug powders?
Reviews of inhalable particles report that aerodynamic diameters of about 1 to 5 micrometres suit aerosol generation and lung deposition. Mass median aerodynamic diameter and fine particle fraction describe how a powder performs.
Cohesiveness rises for particles smaller than 1 micrometre and falls for those larger than 5 micrometres, and the 1 to 5 micrometre range shows optimum cohesiveness for aerosolisation.
The target for a specific product comes from development data and the inhaler device, not from a general rule.
What problems can jet milling cause?
A review of dry powder inhaler stability reports that jet-milled powder is often extremely cohesive and prone to strong agglomeration, because surface energy and electrostatic charge increase.
Excess milling energy can also cause mechanical activation and local amorphous sites at the particle surface. These sites can recrystallise during storage at high humidity and change the powder.
The remedies are conditioning, coating the particles, co-milling with additives and, for some products, a different route.
What is conditioning after micronization?
Conditioning means holding the milled powder under controlled humidity and temperature so that amorphous content recrystallises in a controlled way. The temperature is kept above the glass transition temperature, and absorbed water lowers that temperature and raises molecular mobility.
The review reports that accelerated temperature and humidity exposure can improve post-micronization stability by reducing amorphous content and the aggregation linked to it.
The conditioning step should be part of the development record, with the milled and conditioned powder tested for size and solid state.
Which guidelines apply to micronized APIs?
ICH Q6A says particle size distribution testing should be carried out, with acceptance criteria, where particle size has a significant effect on dissolution rate, bioavailability or stability. It also says the appropriate solid state should be specified where polymorphic forms, including amorphous forms, affect performance.
ICH Q7 states that physical manipulation of particle size, such as milling and micronizing, should be conducted at least to the standards of that guide. It uses residue on the wall of a micronizer as an example of batch-to-batch carry-over.
Laser diffraction, described in USP chapter 429 and ISO 13320, is the usual way to report D10, D50 and D90.
Micronizing or Engineering a Drug Substance?
Global Formulation supports mill and parameter screening, solid-state characterisation, conditioning studies, specifications and transfer to a qualified CDMO.
Talk to Our Formulation Team